Press Releases

BrainStorm Cell Therapeutics to Present at Rodman & Renshaw 17th Annual Global Investment Conference

HACKENSACK, N.J. and PETACH TIKVAH, Israel, Sept. 2, 2015 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, announced today that Chief Executive Officer Tony Fiorino, MD, PhD, will present a corporate update at the Rodman & Renshaw 17th Annual Global Investment Conference sponsored by H.C. Wainwright & Co. taking place September 8-10, 2015 at The St. Regis Hotel in New York, NY.  Presentation and webcast details are as follows:

BrainStorm Cell Therapeutics

Rodman & Renshaw 17th Annual Global Investment Conference

Date: Thursday, September 10, 2015
Time: 10:00-10:25 AM ET
Location: St. Regis Hotel, New York, NY
Room: Library (2nd Floor)

The webcast may be accessed through the above link during the presentation and for 90 day afterwards.

About BrainStorm Cell Therapeutics Inc.
BrainStorm Cell Therapeutics Inc. is a biotechnology company engaged in the development of first-of-its-kind adult stem cell therapies derived from autologous bone marrow cells for the treatment of neurodegenerative diseases. The Company holds the rights to develop and commercialize its NurOwn® technology through an exclusive, worldwide licensing agreement with Ramot, the technology transfer company of Tel Aviv University.  NurOwn® has been administered to over 50 patients with ALS in clinical trials conducted in Israel and the United States, including the current randomized, double-blind, placebo-controlled clinical trial in the United States.  For more information, visit the company's website at

Logo -

To view the original version on PR Newswire, visit:

SOURCE BrainStorm Cell Therapeutics Inc.

For further information: Media: Tony Fiorino, MD, PhD, Chief Executive Officer, BrainStorm Cell Therapeutics Inc., 201-488-0460,; Investors: Michael Wood, LifeSci Advisors, LLC, 646-597-6983,
Email Alerts
Investor Contact
Investor FAQs
RSS Feeds